Overview Dividends

(ALDX) Aldeyra The - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US01438T1060

Reproxalap, ADX-2191, ADX-629, RASP Platform

Biotechnology
Market Cap in USD: 310m
IPO / Inception: 2014-05-02
Return 12m vs S&P 500: -31.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of ALDX over the last years for every Quarter: "2020-12": -0.3, "2021-03": -0.25, "2021-06": -0.28, "2021-09": -0.27, "2021-12": -0.27, "2022-03": -0.29, "2022-06": -0.3, "2022-09": -0.25, "2022-12": -0.22, "2023-03": -0.27, "2023-06": -0.15, "2023-09": -0.14, "2023-12": -0.08, "2024-03": -0.14, "2024-06": -0.28, "2024-09": -0.25, "2024-12": -0.27, "2025-03": -0.17, "2025-06": -0.16, "2025-09": -0.13, "2025-12": 0,
EPS CAGR: 88.76%
EPS Trend: 57.2%
Last SUE: 2.98
Qual. Beats: 3

Revenue

Revenue of ALDX over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.39262, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.244526, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: null,
Rev. CAGR: 0.00%
Rev. Trend: 16.3%
Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 122%
Value at Risk 5%th 128%
Relative Tail Risk -35.96%
Reward TTM
Sharpe Ratio 0.59
Alpha -41.26
CAGR/Max DD -0.15
Character TTM
Hurst Exponent 0.474
Beta 0.980
Beta Downside 1.872
Drawdowns 3y
Max DD 88.06%
Mean DD 52.44%
Median DD 56.56%

Description: ALDX Aldeyra The December 31, 2025

Aldeyra Therapeutics (NASDAQ: ALDX) is a U.S.-based biotech focused on immune-mediated and metabolic disorders. Its flagship candidate, reproxalap-a reactive aldehyde species (RASP) modulator-is in Phase III trials for dry-eye disease and allergic conjunctivitis. The pipeline also includes ADX-2191 for retinitis pigmentosa, ADX-629 (oral RASP modulator) in Phase II for COVID-19, atopic asthma, psoriasis, and alcohol intoxication, plus several preclinical RASP platforms targeting broader inflammatory and metabolic indications.

As of the most recent filing (Q2 2024), Aldeyra reported a cash runway of roughly $45 million, sufficient to fund operations into late 2025 assuming current burn rates (~$12 million per quarter). The biotech sector’s R&D intensity remains high, with average Phase III success rates around 30 % for ophthalmology indications, suggesting a material upside if reproxalap meets its primary endpoints. Additionally, the company’s market cap (~$150 million) is modest relative to peers, implying a higher potential upside but also greater volatility; any delay in trial timelines could materially affect valuation.

If you’re evaluating niche biotech opportunities, a quick look at ValueRay’s analyst notes on ALDX could help surface quantitative risk metrics and comparable peer benchmarks.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-43.2m TTM) > 0 and > 6% of Revenue (6% = 14.7k TTM)
FCFTA -0.52 (>2.0%) and ΔFCFTA -25.38pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 20.0k% (prev 25.4k%; Δ -5331 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.52 (>3.0%) and CFO -40.1m > Net Income -43.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (60.1m) change vs 12m ago 1.00% (target <= -2.0% for YES)
Gross Margin -2.75% (prev 35.89%; Δ -38.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.25% (prev 0.33%; Δ -0.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -21.72 (EBITDA TTM -41.0m / Interest Expense TTM 1.90m) >= 6 (WARN >= 3)

Altman Z'' -36.28

(A) 0.63 = (Total Current Assets 77.5m - Total Current Liabilities 28.5m) / Total Assets 77.8m
(B) -6.14 = Retained Earnings (Balance) -477.5m / Total Assets 77.8m
warn (B) unusual magnitude: -6.14 — check mapping/units
(C) -0.42 = EBIT TTM -41.3m / Avg Total Assets 97.6m
(D) -16.72 = Book Value of Equity -477.4m / Total Liabilities 28.6m
Total Rating: -36.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 58.71

1. Piotroski 0.50pt
2. FCF Yield -16.03%
3. FCF Margin data missing
4. Debt/Equity 0.32
5. Debt/Ebitda 1.07
6. ROIC - WACC (= 149.8)%
7. RoE -72.25%
8. Rev. Trend 16.33%
9. EPS Trend 57.20%

What is the price of ALDX shares?

As of January 08, 2026, the stock is trading at USD 4.16 with a total of 883,136 shares traded.
Over the past week, the price has changed by -19.69%, over one month by -15.96%, over three months by -25.85% and over the past year by -18.59%.

Is ALDX a buy, sell or hold?

Aldeyra The has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy ALDX.
  • Strong Buy: 5
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ALDX price?

Issuer Target Up/Down from current
Wallstreet Target Price 9.7 132.5%
Analysts Target Price 9.7 132.5%
ValueRay Target Price 3.9 -5.3%

ALDX Fundamental Data Overview January 01, 2026

Market Cap USD = 309.8m (309.8m USD * 1.0 USD.USD)
P/B = 6.2918
Beta = 0.821
Revenue TTM = 244.5k USD
EBIT TTM = -41.3m USD
EBITDA TTM = -41.0m USD
Long Term Debt = 15.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 15.5m USD (from shortTermDebt, last quarter)
Debt = 15.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.8m USD (from netDebt column, last quarter)
Enterprise Value = 250.1m USD (309.8m + Debt 15.5m - CCE 75.3m)
Interest Coverage Ratio = -21.72 (Ebit TTM -41.3m / Interest Expense TTM 1.90m)
FCF Yield = -16.03% (FCF TTM -40.1m / Enterprise Value 250.1m)
FCF Margin = -16.4k% (FCF TTM -40.1m / Revenue TTM 244.5k)
Net Margin = -17.7k% (Net Income TTM -43.2m / Revenue TTM 244.5k)
Gross Margin = -2.75% ((Revenue TTM 244.5k - Cost of Revenue TTM 251.2k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.21 (Enterprise Value 250.1m / Total Assets 77.8m)
Interest Expense / Debt = 3.06% (Interest Expense 475.9k / Debt 15.5m)
Taxrate = 100.0m% (out of range, set to none) (-55851.44b / -55.9m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.72 (Total Current Assets 77.5m / Total Current Liabilities 28.5m)
Debt / Equity = 0.32 (Debt 15.5m / totalStockholderEquity, last quarter 49.2m)
Debt / EBITDA = 1.07 (negative EBITDA) (Net Debt -43.8m / EBITDA -41.0m)
Debt / FCF = 1.09 (negative FCF - burning cash) (Net Debt -43.8m / FCF TTM -40.1m)
Total Stockholder Equity = 59.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.52% (Net Income -43.2m / Total Assets 77.8m)
RoE = -72.25% (Net Income TTM -43.2m / Total Stockholder Equity 59.8m)
RoCE = -55.22% (EBIT -41.3m / Capital Employed (Equity 59.8m + L.T.Debt 15.0m))
RoIC = 158.9% (negative operating profit) (EBIT -41.3m / (Assets 77.8m - Curr.Liab 28.5m - Cash 75.3m))
WACC = 9.17% (E(309.8m)/V(325.4m) * Re(9.63%) + (debt cost/tax rate unavailable))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.78%
Fair Price DCF = unknown (Cash Flow -40.1m)
EPS Correlation: 57.20 | EPS CAGR: 88.76% | SUE: 2.98 | # QB: 3
Revenue Correlation: 16.33 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.33 | Chg30d=-0.280 | Revisions Net=+1 | Growth EPS=+154.9% | Growth Revenue=+152.8%

Additional Sources for ALDX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle